Involving stemness factors to improve CAR T-cell-based cancer immunotherapy

• Published in: Medical oncology (Northwood, London, England) Vol. 40; no. 11; p. 313
• Main Authors: Noraldeen, Sara Abdalrazzaq M., Rasulova, Irodakhon, Lalitha, Repudi, Hussin, Farah, Alsaab, Hashem O., Alawadi, Ahmed Hussien, Alsaalamy, Ali, Sayyid, Nidhal Hassan, Alkhafaji, Adnan Taan, Mustafa, Yasser Fakri, Shayan, Sepideh Karkon
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.10.2023; Springer Nature B.V
• Subjects: Antigens; Cancer; Engineering; Glycoproteins; Hematology; Immunotherapy; Internal Medicine; Kinases; Lymphocytes; Lymphoma; Medicine; Medicine & Public Health; Oncology; Pathology; Pharmaceuticals; Review Article; Stem cells; Toxicity; Tumors; Cancer stem cell; Stemness; Oncolytic virus; Tumor microenvironment; Adoptive cell therapy; iPSC
• ISSN: 1559-131X; 1357-0560; 1559-131X
• DOI: 10.1007/s12032-023-02191-7

Treatment with chimeric antigen receptor (CAR) T cells indicated remarkable clinical responses with liquid cancers such as hematological malignancies; however, their therapeutic efficacy faced with many challenges in solid tumors due to severe toxicities, antigen evasion, restricted and limited tumor tissue trafficking and infiltration, and, more importantly, immunosuppressive tumor microenvironment (TME) factors that impair the CAR T-cell function adds support survival of cancer stem cells (CSCs), responsible for tumor recurrence and resistance to current cancer therapies. Therefore, in-depth identification of TME and development of more potent CAR platform targeting CSCs may overcome the raised challenges, as presented in this review. We also discuss recent stemness-based innovations in CAR T-cell production and engineering to improve their efficacy in vivo, and finally, we propose solutions and strategies such as oncolytic virus-based therapy and combination therapy to revive the function of CAR T-cell therapy, especially in TME of solid tumors in future.